Loading organizations...
QSM Diagnostics develops point-of-care veterinary diagnostics, offering mail-in testing kits and in-clinic instruments for rapid bacterial infection identification in pets. Leveraging its patented Quorum Sensing Technology, the company provides accurate, timely results, enhancing treatment and addressing antimicrobial resistance in animal health. This innovation simplifies diagnostics for veterinarians and owners.
Edgar Goluch founded QSM Diagnostics in 2014, from research at Northeastern University. His core insight involved swiftly identifying and quantifying bacteria by analyzing secreted molecules. This breakthrough established an efficient diagnostic method, surpassing traditional culture-based approaches and delivering quicker pet health insights.
The company serves veterinarians and pet owners, enabling earlier, more precise diagnoses for pet ailments. QSM Diagnostics aims to fundamentally change how bacterial infections are diagnosed and treated in pets, thereby improving animal welfare and promoting responsible antibiotic application in veterinary medicine.
QSM Diagnostics has raised $2.0M across 1 funding round.
QSM Diagnostics has raised $2.0M in total across 1 funding round.
QSM Diagnostics has raised $2.0M in total across 1 funding round.
QSM Diagnostics's investors include Maroon Venture Partners Fund.
QSM Diagnostics has raised $2.0M across 1 funding round. Most recently, it raised $2.0M Seed in July 2018.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jul 1, 2018 | $2M Seed | — | Maroon Venture Partners Fund | Announced |
QSM Diagnostics is a veterinary diagnostics startup founded in 2014 and based in the Boston area (Woburn/Boston, MA), developing patented Quorum Sensing Technology for rapid bacterial infection detection in companion animals like dogs and cats[1][2][3]. It offers two main product lines: FetchDx mail-in testing kits for pre- and post-visit diagnostics, where pet owners collect samples and ship them to QSM's lab, and the Otter eQ in-clinic platform for point-of-care testing that delivers results in minutes[1][2][3][5]. These tools serve veterinarians and pet owners (B2B2C model), solving the problem of slow, labor-intensive bacterial testing that delays treatment, reduces accuracy, and contributes to antimicrobial resistance by enabling faster, data-driven antibiotic decisions—starting with high-prevalence issues like dog ear infections and expanding to urinary tract infections[1][2][3][5]. With products in market, ~6 employees, and $260K raised, the company shows steady growth via accessible kits that integrate into vet workflows without new equipment[1][2][5].
QSM Diagnostics was founded in October 2014 by Dr. Edgar Goluch, a PhD in bioengineering and tenured associate professor in chemical engineering at Northeastern University with 15+ years in sensors, diagnostics, and lab-on-a-chip tech[1][2]. Goluch identified a critical gap in veterinary care—undiagnosed bacterial infections in pets, especially common ones like dog ear issues (top reason for vet visits)—and pivoted his advanced Quorum Sensing Technology from broader applications to vet diagnostics for its high demand and unmet need[2][5]. Early focus honed on problematic bacteria for ears, then urinary tracts; pivotal shifts included launching FetchDx mail-in kits ~6 months before recent interviews (pre-2025) to bypass clinic bottlenecks during high-demand periods, allowing pet-owner sample collection and lab processing for quick results[5]. Leadership expanded with Dr. Bowman (VMD from UPenn, 20+ years in animal health for vet education/customer relations) and a project management expert (MBA, 20+ years across biotech/ag sectors), driving from R&D to market[1].
QSM stands out in veterinary diagnostics through its proprietary, patented Quorum Sensing Technology, which "spies" on bacteria for rapid detection without complex lab setups[1][2][3][4]. Key strengths include:
QSM rides the explosive pet care market boom—200M+ dogs/cats in the U.S., 900M globally—with rising humanization of pets driving demand for faster, affordable diagnostics amid vet shortages and post-pandemic backlogs[2][5]. Timing aligns with antimicrobial resistance crises in vet med, where rapid bacterial ID curbs overuse of broad-spectrum antibiotics, plus tech trends in point-of-care (POC) devices and at-home testing (e.g., lab-on-chip, Optimer binders)[2][3][4]. Market tailwinds include vet consolidation, telehealth integration, and consumer shift to proactive pet health; QSM influences by modernizing workflows, enabling same-day decisions, and lowering barriers for smaller clinics—pioneering quorum sensing in vet space to disrupt lab-dependent models[1][3][5].
QSM's dual-kit/instrument model positions it for scaled growth as vet capacity normalizes, with R&D expanding test menus (beyond ears/UTIs) and in-clinic adoption rising[5]. Trends like AI-enhanced diagnostics, global pet ownership surge, and resistance-fighting regs will propel it; partnerships (e.g., Aptamer's Optimer) signal POC innovations for broader pathogens[4]. Influence may evolve via full lab suites, international expansion, or acquisitions in the $10B+ vet diagnostics sector, solidifying its role in precise, accessible pet care—echoing its founding mission to transform infection treatment from reactive delays to proactive wins[2][3].
